Marion S. Buckwalter

Marion S. Buckwalter

Auto-generated profile, based on publicly available information

Marion S. Buckwalter

Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, USA

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2017 in Nature
Verified
Journal Article
Closed access
PDF file
SLShane Liddelow
Shane Liddelow
KGKevin A. Guttenplan
Kevin A. Guttenplan
LCLaura E. Clarke
Laura E. Clarke
FBFrederick C. Bennett
Frederick C. Bennett
CBChristopher J. Bohlen
Christopher J. Bohlen
BBBen A. Barres
Ben A. Barres

1 June 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CICostantino Iadecola
Costantino Iadecola
MBMarion S. Buckwalter
Marion S. Buckwalter
JAJosef Anrather
Josef Anrather
Stroke is the second leading cause of death worldwide and a leading cause of disability. Most strokes are caused by occlusion of a major cerebral artery, and substantial advances have been made in elucidating how ischemia damages the brain. In particular, increasing evidence points to a double-edged role of the immune system in stroke pathophysiology. In the acute phase, innate immune cells invade brain and meninges and contribute to ischemic damage, but may also be protective. At the same time, danger signals released into the circulation by damaged brain cells lead to activation of systemic immunity, followed by profound immunodepression that promotes life-threatening infections. In the chronic phase, antigen presentation initiates an adaptive immune response targeted to the brain, which may underlie neuropsychiatric sequelae, a considerable cause of poststroke morbidity. Here, we briefly review these pathogenic processes and assess the potential therapeutic value of targeting immunity in human stroke.

13 May 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
HYHanadie Yousef
Hanadie Yousef
CCCathrin J. Czupalla
Cathrin J. Czupalla
DLDavis Lee
Davis Lee
MCMichelle B. Chen
Michelle B. Chen
ABAshley N. Burke
Ashley N. Burke
TWTony Wyss-Coray
Tony Wyss-Coray

15 April 2022 in Circulation Research
Verified
Journal Article
Closed access
PDF file
MEMatthias Endres
Matthias Endres
MMMaria A. Moro
Maria A. Moro
CNChristian H. Nolte
Christian H. Nolte
CDClaudia Dames
Claudia Dames
MBMarion S. Buckwalter
Marion S. Buckwalter
AMAndreas Meisel
Andreas Meisel
Inflammation and immune mechanisms are crucially involved in the pathophysiology of the development, acute damage cascades, and chronic course after ischemic stroke. Atherosclerosis is an inflammatory disease, and, in addition to classical risk factors, maladaptive immune mechanisms lead to an increased risk of stroke. Accordingly, individuals with signs of inflammation or corresponding biomarkers have an increased risk of stroke. Anti-inflammatory drugs, such as IL (interleukin)-1β blockers, methotrexate, or colchicine, represent attractive treatment strategies to prevent vascular events and stroke. Lately, the COVID-19 pandemic shows a clear association between SARS-CoV2 infections and increased risk of cerebrovascular events. Furthermore, mechanisms of both innate and adaptive immune systems influence cerebral damage cascades after ischemic stroke. Neutrophils, monocytes, and microglia, as well as T and B lymphocytes each play complex interdependent roles that synergize to remove dead tissue but also can cause bystander injury to intact brain cells and generate maladaptive chronic inflammation. Chronic systemic inflammation and comorbid infections may unfavorably influence both outcome after stroke and recurrence risk for further stroke. In addition, stroke triggers specific immune depression, which in turn can promote infections. Recent research is now increasingly addressing the question of the extent to which immune mechanisms may influence long-term outcome after stroke and, in particular, cause specific complications such as poststroke dementia or even poststroke depression.

4 February 2015 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
KDKristian Doyle
Kristian Doyle
LQLisa N. Quach
Lisa N. Quach
Montse SoléMontse Solé
Montse Solé
RARobert C. Axtell
Robert C. Axtell
TNThuy-Vi V. Nguyen
Thuy-Vi V. Nguyen
MBMarion S. Buckwalter
Marion S. Buckwalter
Each year, 10 million people worldwide survive the neurologic injury associated with a stroke. Importantly, stroke survivors have more than twice the risk of subsequently developing dementia compared with people who have never had a stroke. The link between stroke and the later development of dementia is not understood. There are reports of oligoclonal bands in the CSF of stroke patients, suggesting that in some people a B-lymphocyte response to stroke may occur in the CNS. Therefore, we tested the hypothesis that a B-lymphocyte response to stroke could contribute to the onset of dementia. We discovered that, in mouse models, activated B-lymphocytes infiltrate infarcted tissue in the weeks after stroke. B-lymphocytes undergo isotype switching, and IgM, IgG, and IgA antibodies are found in the neuropil adjacent to the lesion. Concurrently, mice develop delayed deficits in LTP and cognition. Genetic deficiency, and the pharmacologic ablation of B-lymphocytes using an anti-CD20 antibody, prevents the appearance of delayed cognitive deficits. Furthermore, immunostaining of human postmortem tissue revealed that a B-lymphocyte response to stroke also occurs in the brain of some people with stroke and dementia. These data suggest that some stroke patients may develop a B-lymphocyte response to stroke that contributes to dementia, and is potentially treatable with FDA-approved drugs that target B cells.

1 June 2015 in Neurobiology of Disease
Verified
Journal Article
Closed access
IWItai Weissberg
Itai Weissberg
LWLydia Wood
Lydia Wood
LKLyn Kamintsky
Lyn Kamintsky
OVOscar Vazquez
Oscar Vazquez
DMDan Z. Milikovsky
Dan Z. Milikovsky
DKdaniela kaufer
daniela kaufer